Bluebird Bio Cmn (BLUE) 57.18 $BLUE bluebird bio

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 4:16 AM

Bluebird Bio Cmn (BLUE) 57.18 $BLUE

bluebird bio Presents megaTAL Genome Editing Data at American Society of Hematology (ASH) Workshop on Genome Editing
BusinessWire - Mon Jul 18, 7:30AM CDT
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the presentation of pre-clinical data from its megaTAL genome editing platform at the ASH Workshop on Genome Editing, held July 14-15 in Washington, D.C.
BLUE: 57.18 (+1.09)

Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold
Arpita Dutt - Zacks Investment Research - Wed Jul 13, 4:46AM CDT
Juno's (JUNO) shares were up in after-market hours following the lifting of the clincal hold on the company's pivotal ROCKET study.
MACK: 5.80 (+0.19), BLUE: 57.18 (+1.09), KITE: 56.63 (+2.11), JUNO: 30.93 (+1.02)

Why is Juno Therapeutics (JUNO) Stock Plunging 31% Today?
Madeleine Johnson - Zacks Investment Research - Fri Jul 08, 11:01AM CDT
On Friday, shares of biopharmaceutical company Juno Therapeutics Inc. (JUNO) are plunging, down around 31% as of 10:36 AM EST after three patients died in a trial for its leading cancer therapy.
BLUE: 57.18 (+1.09), KITE: 56.63 (+2.11), JUNO: 30.93 (+1.02)

Juno (JUNO) Suffers Setback, Pivotal Study on Clinical Hold
Arpita Dutt - Zacks Investment Research - Fri Jul 08, 7:44AM CDT
Juno's (JUNO) shares were down in pre-market trading with the FDA placing its pivotal study on clinical hold.
BLUE: 57.18 (+1.09), BIIB: 289.93 (+0.90), KITE: 56.63 (+2.11), JUNO: 30.93 (+1.02)

AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 57.18 (+1.09), SQNM: 2.36 (-0.01), TSRO: 93.24 (-0.38), NKTR: 17.29 (+1.19)

bluebird bio to Present at Goldman Sachs 37th Annual Healthcare Conference
BusinessWire - Mon May 23, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the Goldman Sachs 37th Annual Healthcare Conference on June 8, 2016 at 8:00 am PT (11:00 am ET). The conference is being held June 7-9, 2016 at the Terranea Resort in Rancho Palos Verdes, Calif.
BLUE: 57.18 (+1.09)

Join Victory Living Programs to Host 6th Annual Black and Blue Dine Around Event at Blue Martini and The Capital Grille in Fort Lauderdale
PR Newswire - Thu May 12, 9:00AM CDT
Victory Living Programs' Annual Black and Blue Dine Around event, held this year on Sunday, June 5, 2016 at 5:30 p.m., offers a unique dining and dancing experience complete with cocktails, dinner and dessert.
BLUE: 57.18 (+1.09)

bluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting
BusinessWire - Mon May 09, 7:30AM CDT
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced the presentation of pre-clinical data from its immuno-oncology and hematopoietic stem cell (HSC) gene therapy programs at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, taking place May 4-7, 2016 in Washington, D.C.
BLUE: 57.18 (+1.09)

bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress
BusinessWire - Wed May 04, 3:05PM CDT
--- Ten abstracts accepted for presentation at American Society for Gene and Cell Therapy (ASGCT) Meeting -
BLUE: 57.18 (+1.09)

Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys
Cory Renauer, The Motley Fool - Motley Fool - Tue May 03, 7:03AM CDT
Image source: bluebird bio. Against the mosaic of young, clinical-stage, gene-editing, cellular-therapy biotechs, bluebird bio (NASDAQ: BLUE) stands tall, despite its disdain for uppercase consonants. It has produced some amazing results in small...
BLUE: 57.18 (+1.09), BIIB: 289.93 (+0.90), VRTX: 97.00 (+0.79), MRK: 58.66 (+0.23)

Global Gene Therapy Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Advantagene, Bluebird Bio, Genethon - Research and Markets
BusinessWire - Tue Apr 26, 10:39AM CDT
Research and Markets has announced the addition of the "Global Gene Therapy Market Forecast to 2020" report to their offering.
BLUE: 57.18 (+1.09)

bluebird bio, Inc. Takes Flight Towards First Approval
Cory Renauer, The Motley Fool - Motley Fool - Thu Apr 21, 8:21AM CDT
Image source: bluebird bio, On Wednesday, April 20, at about 8:30AM, gene editing pioneer bluebird bio (NASDAQ: BLUE) reported interim results from the only study running right now that might earn it an FDA approval. Although it's interim data...
BLUE: 57.18 (+1.09)

bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting
BusinessWire - Mon Apr 18, 3:05PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced that data from clinical, preclinical, and research and manufacturing programs will be highlighted in ten presentations at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, taking place May 4-7, 2016 in Washington, D.C.
BLUE: 57.18 (+1.09)

Here's Why bluebird bio.'s Stock Tumbled in March
George Budwell, The Motley Fool - Motley Fool - Tue Apr 12, 8:27AM CDT
What: Shares of the clinical-stage biotech bluebird bio shed nearly 16% of their value last month, according to data from S&P Global Market Intelligence . On the bright side, bluebird's poor showing last month seems to be the result of an...
BLUE: 57.18 (+1.09), IBB: 289.44 (+1.76)

[Podcast] Slingshot Insights and Estimize talk Biotech, Markets, and Forcerank
ESTMZ - Fri Apr 08, 10:42AM CDT
In case you missed it, check out the recording of yesterday’s webinar with Slingshot Insights! Leigh Drogen, Founder of Estimize, joins Joe McCann of Slingshot Insights to talk Biotech stocks, the market, and his latest creation ForceRank....
BLUE: 57.18 (+1.09), BIIB: 289.93 (+0.90), ALNY: 68.08 (-0.21), KITE: 56.63 (+2.11), CELG: 112.19 (+0.93)

Why Bluebird Bio Inc. Plunged Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed Mar 23, 8:48PM CDT
Image source: Bluebird Bio. What: Shares of Bluebird Bio , a clinical-stage biotechnology company focused on gene therapy, dropped by more than 11% on Wednesday. So what: There doesn't appear to be any news to justify such a big move, so...
BLUE: 57.18 (+1.09), XBI: 62.07 (+0.75)

Synlogic Appoints an Industry Leader Nick Leschly to Its Board of Directors
BusinessWire - Wed Mar 23, 7:00AM CDT
Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced the expansion of its Board of Directors with the appointment of Mr. Nick Leschly, CEO of bluebird bio (NASDAQ: BLUE), Inc., as an independent Director.
BLUE: 57.18 (+1.09)

Why bluebird bio Inc Presented a Lower Price Today
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 08, 3:22PM CST
STEPS OF GENE THERAPY. IMAGE SOURCE: BLUEBIRD BIO. What: bluebird bio was down as much as 12% Tuesday, apparently on no news. The stock just started falling from the open and never really recovered. So what: Let's keep this in perspective....
BLUE: 57.18 (+1.09)

bluebird bio to Present Clinical Data on Lenti-D in CALD in Plenary Session at AAN 2016 Annual Meeting
BusinessWire - Thu Mar 03, 3:39PM CST
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from the ongoing Phase 2/3 Starbeam Study (ALD-102) for the treatment of cerebral adrenoleukodystrophy (CALD) will be presented in an oral presentation during the Clinical Trials plenary session on April 20, 2016 at the American Academy of Neurology (AAN) 2016 Annual Meeting. The meeting is being held April 15 - 21, 2016 in Vancouver, BC, Canada.
BLUE: 57.18 (+1.09)

Why bluebird bio Inc.'s Stock Dropped 34% in January
Brian Feroldi, The Motley Fool - Motley Fool - Mon Feb 08, 10:22AM CST
What: January was a month to forget for investors in bluebird bio , a clinical-stage biotechnology company focused on gene therapy. The stock shed more than 34% of its value during the month, according to data from S&P Capital IQ . Bluebird...
BLUE: 57.18 (+1.09), BLCM: 15.88 (+0.13)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Dr. Anderson’s Journey: Leadership with Faith and Service

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...